应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ABEO Abeona Therapeutics Inc
休市中 09-25 16:00:00 EDT
5.40
-0.03
-0.55%
盘后
5.40
+0.00
0.00%
19:30 EDT
最高
5.48
最低
5.34
成交量
72.07万
今开
5.45
昨收
5.43
日振幅
2.58%
总市值
3.08亿
流通市值
1.99亿
总股本
5,705万
成交额
389.26万
换手率
1.95%
流通股本
3,692万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Abeona Therapeutics® 祝贺Ultragenyx获美国FDA批准Fayuvi™基因疗法用于治疗Sanfilippo综合征A型(MPS IIIA)
美股速递 · 09-18
Abeona Therapeutics® 祝贺Ultragenyx获美国FDA批准Fayuvi™基因疗法用于治疗Sanfilippo综合征A型(MPS IIIA)
Abeona Therapeutics宣布佛罗里达大学健康中心成为Zevaskyn®最新合格治疗中心
美股速递 · 09-16
Abeona Therapeutics宣布佛罗里达大学健康中心成为Zevaskyn®最新合格治疗中心
Abeona Therapeutics 计划于2027年下半年提交新药临床试验申请并启动ABO-701首次人体研究
美股速递 · 05-13
Abeona Therapeutics 计划于2027年下半年提交新药临床试验申请并启动ABO-701首次人体研究
Abeona Therapeutics宣布费城儿童医院成为Zevaskyn®新认证治疗中心
美股速递 · 05-11
Abeona Therapeutics宣布费城儿童医院成为Zevaskyn®新认证治疗中心
Abeona Therapeutics Inc.盘中异动 大幅上涨5.13%
市场透视 · 2025-03-05
Abeona Therapeutics Inc.盘中异动 大幅上涨5.13%
Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。
金融界 · 2025-03-05
Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。
Abeona Therapeutics Inc.盘中异动 大幅拉升5.23%报5.54美元
市场透视 · 2025-01-28
Abeona Therapeutics Inc.盘中异动 大幅拉升5.23%报5.54美元
Abeona Therapeutics Inc.盘中异动 股价大涨5.14%报6.34美元
市场透视 · 2024-11-27
Abeona Therapeutics Inc.盘中异动 股价大涨5.14%报6.34美元
Abeona Therapeutics Inc.盘中异动 大幅拉升5.26%报6.20美元
市场透视 · 2024-09-30
Abeona Therapeutics Inc.盘中异动 大幅拉升5.26%报6.20美元
加载更多
公司概况
公司名称:
Abeona Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Abeona Therapeutics, Inc.于1974年在怀俄明州注册成立。该公司是一家处于商业阶段的生物制药公司,为危及生命的疾病开发细胞和基因疗法。2025年4月28日,美国食品药品监督管理局批准了ZEVASKYN(prademagene zamikeracel)基因修饰的细胞片,作为第一种也是唯一一种基于自体细胞的基因疗法,用于治疗成人和儿童RDEB患者的伤口,RDEB是一种严重且令人衰弱的遗传性皮肤病。RDEB无法治愈,ZEVASKYN是唯一一种经美国食品药品监督管理局批准的产品,可以一次性治疗RDEB伤口。ZEVASKYN被美国食品药品监督管理局授予孤儿药和罕见儿科疾病名称。
发行价格:
--
{"stockData":{"symbol":"ABEO","market":"US","secType":"STK","nameCN":"Abeona Therapeutics Inc","latestPrice":5.4,"timestamp":1790366400000,"preClose":5.43,"halted":0,"volume":720707,"hourTrading":{"tag":"盘后","latestPrice":5.4,"preClose":5.4,"latestTime":"19:30 EDT","volume":19294,"amount":104199.6168,"timestamp":1790379007157,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005524861878452921,"floatShares":36919500,"shares":57049023,"eps":-1.12,"marketStatus":"休市中","change":-0.03,"latestTime":"09-25 16:00:00 EDT","open":5.45,"high":5.475,"low":5.335,"amount":3892557.3895234005,"amplitude":0.025783,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.12,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.43,"preHourTrading":{"tag":"盘前","latestPrice":5.45,"preClose":5.43,"latestTime":"09:29 EDT","volume":193,"amount":1058.7316079999998,"timestamp":1790342966000,"change":0.02,"changeRate":0.003683,"amplitude":0.034604},"postHourTrading":{"tag":"盘后","latestPrice":5.4,"preClose":5.4,"latestTime":"19:30 EDT","volume":19294,"amount":104199.6168,"timestamp":1790379007157,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.526215,"impliedVol":1.3792,"impliedVolPercentile":0.6056},"requestUrl":"/m/hq/s/ABEO","defaultTab":"news","newsList":[{"id":"1158473879","title":"Abeona Therapeutics® 祝贺Ultragenyx获美国FDA批准Fayuvi™基因疗法用于治疗Sanfilippo综合征A型(MPS IIIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=1158473879","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158473879?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:32","pubTimestamp":1789731172,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics® 对Ultragenyx表示祝贺,因其Fayuvi™基因疗法获得美国食品药品监督管理局(FDA)批准,用于治疗Sanfilippo综合征A型(即黏多糖贮积症IIIA型,MPS IIIA)。\n此项批准标志着该罕见病治疗领域的重要里程碑。Abeona Therapeutics向Ultragenyx团队致以诚挚祝贺,认可其在推进这一创新疗法方面所做出的不懈努力与卓越贡献。\nFayuvi™作为一种基因疗法,旨在通过靶向修复相关基因缺陷来应对这一严重且目前尚无治愈手段的遗传性疾病。此次获批无疑为受Sanfilippo综合征A型影响的患儿及其家庭带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176745281","title":"Abeona Therapeutics宣布佛罗里达大学健康中心成为Zevaskyn®最新合格治疗中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1176745281","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176745281?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:31","pubTimestamp":1789558270,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Inc今日宣布,佛罗里达大学健康中心已正式启用,成为Zevaskyn疗法的又一合格治疗中心。作为一家专注于开发严重疾病新型基因疗法的生物制药企业,Abeona Therapeutics此次与佛罗里达大学健康中心的合作,是其持续拓展治疗网络的重要节点。佛罗里达大学健康中心凭借其卓越的临床实力和丰富的患者资源,有望成为Zevaskyn推广过程中一股不可忽视的推动力量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192338179","title":"Abeona Therapeutics 计划于2027年下半年提交新药临床试验申请并启动ABO-701首次人体研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1192338179","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192338179?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:31","pubTimestamp":1778671913,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Inc 宣布,其针对ABO-701的研究计划取得明确进展。该公司预期将在2027年下半年向监管机构提交新药临床试验(IND)申请,并随即启动该候选药物的首次人体临床研究。这一时间表标志着公司研发管线中这一重要项目进入了新的实质性阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142821545","title":"Abeona Therapeutics宣布费城儿童医院成为Zevaskyn®新认证治疗中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1142821545","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142821545?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:35","pubTimestamp":1778502900,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics公司近日宣布,费城儿童医院已被激活,成为其基因疗法Zevaskyn®的新认证治疗中心。此举旨在扩大该创新疗法的可及性,为符合条件的患者提供专业治疗服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517260910","title":"Abeona Therapeutics Inc.盘中异动 大幅上涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517260910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517260910?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185145,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分,Abeona Therapeutics Inc.股票出现异动,股价大幅拉升5.13%。截至发稿,该股报5.33美元/股,成交量6506股,换手率0.01%,振幅0.00%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.20%。其相关个股中,Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Zyversa Therapeutics, Inc.较为活跃,换手率分别为342.41%、257.25%、186.62%,振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.,振幅分别为23.90%、13.51%、13.21%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223225abe9b0fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223225abe9b0fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABEOW","LENZ","ABEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517926917","title":"Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517926917","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517926917?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:04","pubTimestamp":1741183446,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics(ABEO.US)获奥本海默首次覆盖,给予优于大市评级, 目标价16.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05220448547630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","ABEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506304699","title":"Abeona Therapeutics Inc.盘中异动 大幅拉升5.23%报5.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506304699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506304699?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:05","pubTimestamp":1737993938,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日00时05分,Abeona Therapeutics Inc.股票出现波动,股价大幅拉升5.23%。截至发稿,该股报5.54美元/股,成交量9.3329万股,换手率0.21%,振幅5.29%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.84%。其相关个股中,Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大,Onconetix, Inc.、Dogwood Therapeutics, Inc.、Evaxion Biotech As较为活跃,换手率分别为1969.92%、456.49%、218.44%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为86.84%、85.35%、65.16%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280005389612481b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280005389612481b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ABEOW","BK4139","ABEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486087345","title":"Abeona Therapeutics Inc.盘中异动 股价大涨5.14%报6.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486087345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486087345?lang=zh_cn&edition=full","pubTime":"2024-11-27 23:08","pubTimestamp":1732720109,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日23时08分,Abeona Therapeutics Inc.股票出现异动,股价快速拉升5.14%。截至发稿,该股报6.34美元/股,成交量7.1051万股,换手率0.16%,振幅4.89%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.38%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127230830abe37c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127230830abe37c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ABEOW","ABEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2471638995","title":"Abeona Therapeutics Inc.盘中异动 大幅拉升5.26%报6.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471638995","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2471638995?lang=zh_cn&edition=full","pubTime":"2024-09-30 22:08","pubTimestamp":1727705304,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日22时08分,Abeona Therapeutics Inc.股票出现波动,股价大幅上涨5.26%。截至发稿,该股报6.20美元/股,成交量7.7815万股,换手率0.18%,振幅5.26%。Abeona Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.11%。Abeona Therapeutics Inc.公司简介:Abeona Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930220824ab672922&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930220824ab672922&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABEOW","ABEO","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abeonatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":-0.1015},{"period":"3month","weight":-0.0374},{"period":"6month","weight":0.2587},{"period":"1year","weight":0.0075},{"period":"ytd","weight":0.0247}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abeona Therapeutics, Inc.于1974年在怀俄明州注册成立。该公司是一家处于商业阶段的生物制药公司,为危及生命的疾病开发细胞和基因疗法。2025年4月28日,美国食品药品监督管理局批准了ZEVASKYN(prademagene zamikeracel)基因修饰的细胞片,作为第一种也是唯一一种基于自体细胞的基因疗法,用于治疗成人和儿童RDEB患者的伤口,RDEB是一种严重且令人衰弱的遗传性皮肤病。RDEB无法治愈,ZEVASKYN是唯一一种经美国食品药品监督管理局批准的产品,可以一次性治疗RDEB伤口。ZEVASKYN被美国食品药品监督管理局授予孤儿药和罕见儿科疾病名称。","yearOnYearQuotes":[{"month":1,"riseRate":0.090909,"avgChangeRate":-0.103016},{"month":2,"riseRate":0.636364,"avgChangeRate":0.111579},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.009228},{"month":4,"riseRate":0.727273,"avgChangeRate":0.040154},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.004224},{"month":6,"riseRate":0.363636,"avgChangeRate":0.009166},{"month":7,"riseRate":0.5,"avgChangeRate":-0.011191},{"month":8,"riseRate":0.583333,"avgChangeRate":0.059801},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.015559},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.003904},{"month":11,"riseRate":0.454545,"avgChangeRate":0.087228},{"month":12,"riseRate":0.181818,"avgChangeRate":-0.137446}],"exchange":"NASDAQ","name":"Abeona Therapeutics Inc","nameEN":"Abeona Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abeona Therapeutics Inc(ABEO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abeona Therapeutics Inc(ABEO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abeona Therapeutics Inc,ABEO,Abeona Therapeutics Inc股票,Abeona Therapeutics Inc股票老虎,Abeona Therapeutics Inc股票老虎国际,Abeona Therapeutics Inc行情,Abeona Therapeutics Inc股票行情,Abeona Therapeutics Inc股价,Abeona Therapeutics Inc股市,Abeona Therapeutics Inc股票价格,Abeona Therapeutics Inc股票交易,Abeona Therapeutics Inc股票购买,Abeona Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abeona Therapeutics Inc(ABEO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abeona Therapeutics Inc(ABEO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}